-
Mashup Score: 13Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial - 7 month(s) ago
Key Points. NRD is not inferior to traditional PD during neutropenia after HSCT.Multiple myeloma diagnosis, antibiotic prophylaxis, and absence of mucositis red
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group - PubMed - 7 month(s) ago
Pakistan is the fifth most populous country with a population of 225 million and has health expenditure accounting for only 2.8 percent of gross domestic product (GDP). Accordingly, there are a limited number of haematology-oncology and transplant centers in the country. The Pakistan Blood and Marro …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group #bmtsm @UzmaZaidi19 @DQBMD @MediHumdani @szusmani @TalhaBadarMD @sairah__ahmed https://t.co/TpK4RXyiP8
-
-
Mashup Score: 0Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy - PubMed - 7 month(s) ago
Induction therapy followed by CD34+ cell mobilisation and autologous transplantation represents standard of care for multiple myeloma (MM). However, the anti-CD38 monoclonal antibodies daratumumab and isatuximab have been associated with mobilisation impairment, yet the mechanism remains …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Insight into the mechanism of CD34+ cell mobilization impairment in multiple myeloma patients treated with anti-CD38 therapy. Upregulated adhesion-related interactions may be the leading cause #mmsm #bmtsm https://t.co/2YsGs0Rexx
-
-
Mashup Score: 0The story of the development of generic lenalidomide: How one company thwarted the Waxman-Hatch Act to generate billions of dollars in revenue - 7 month(s) ago
Lenalidomide (Revlimid®) was originally approved by the Food and Drug Administration (FDA) in 2005, however, a generic version was not available until…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The story of the development of generic lenalidomide: How one company thwarted the Waxman-Hatch Act to generate billions of dollars in revenue #mmsm @ManniMD1 @RBeechPharmD @DavidP4AD @MedlawDan #mmsm #bmtsm https://t.co/otUT4sQ3If
-
-
Mashup Score: 4
Caregivers (i.e., family and friends) are essential in providing care and support for patients undergoing hematopoietic cell transplantation (HCT) and…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
8/📘For a deep dive into our research, understanding the nuances of inpatient vs outpatient care, & grasping the intricate experiences of caregivers, do check out our article! Your feedback & experiences will be invaluable to us. #HCTCaregiverStudy #BMTsm https://t.co/pYSM7Ui9xP
-
1/🧪 Excited to share insights from our article from lead author @TamrynGray PhD (at @DanaFarber). We dive deep into the caregiver experience in both inpatient and outpatient settings post-HCT through this qualitative study. 🏥🏡 #HCTCaregiverStudy #BMTsm https://t.co/pYSM7Ui9xP
-
-
Mashup Score: 2
High-dose chemotherapy and autologous HSCT was associated with an increased risk of non-melanoma skin cancer and myelodysplastic syndrome or AML but not with increased risk of solid tumours in patients treated for lymphoma. These findings are relevant for future individualised risk–benefit assessments when choosing between high-dose chemotherapy and autologous HSCT and chimeric antigen receptor T-cell therapy in this setting.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autoSCT: a population-based, retrospective cohort study #bmtsm #lymsm @TheLancetHaem https://t.co/VUQhDAbWxs
-
-
Mashup Score: 0
This approach provided positive outcomes and a pathway for treatment cessation in most patients with newly diagnosed multiple myeloma. Outcomes for patients with ultra-high-risk multiple myeloma, defined as those with two or more HRCAs, remain unsatisfactory, and these patients should be prioritised for trials with early introduction of therapies with novel mechanisms of action.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MRD response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial - @TheLancetHaem @End_myeloma #mmsm #bmtsm https://t.co/xUHniwVbfw
-
-
Mashup Score: 0MRD-guided treatment cessation in multiple myeloma - 7 month(s) ago
Minimal residual disease (MRD) entered the scientific lexicon in 1973, with the promise of immunotherapy to reduce tumour burden so that only MRD remained.1 The term has since taken on a different meaning in multiple myeloma to denote the persistence of low-level disease.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MRD-guided treatment cessation in multiple myeloma - @bdermanmd #bmtsm #mmsm @TheLancetHaem https://t.co/WhV2MXTJnx
-
-
Mashup Score: 1Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies - 7 month(s) ago
The primary goal of the initial treatment in systemic light chain amyloidosis is to obtain a rapid and profound haematological response as safely as possible, coupled with supportive care by a multidisciplinary team. The treatment landscape has evolved with the introduction of highly effective therapies targeting the plasma cell clones, which can attain high rates of haematological complete response with minimal treatment-related morbidity and mortality. Consequently, the role of high-dose melphalan followed by autologous haematopoietic cell transplantation (HDM-AHCT) is being analysed, particularly considering the absence of randomised controlled trial data supporting its superiority over standard-dose therapies in systemic light chain amyloidosis treatment.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies @rajshekharucms @MorieGertz #bmtsm #mmsm https://t.co/2QSsVcmDgw
-
-
Mashup Score: 2La SEHH presenta las Guías en Cardio-Oncología 2022 para hematólogos - 7 month(s) ago
La Sociedad Española de Hematología y Hemoterapia (SEHH) ha presentado las Guías en Cardio-Oncología 2022…
Source: www.infosalus.comCategories: Hem/Oncs, Latest HeadlinesTweet-
La @sehh_es presenta las Guías en Cardio-Oncología 2022 para hematólogos en el Aula Magna de la @Hospital_FJD #CardioOnc @TeresaLpezFdez1 #lymsm #mmsm #leusm #bmtsm #CARTcell https://t.co/VmJ8kjG2sm
-
Nonrestrictive diet is not inferior to traditional protective diet during the neutropenic phase after HSCT (auto or allo). Hopefully, all centers will soon stop using restrictive diets, an unnecessary burden for patients’ quality of life. 👉https://t.co/chaLp2xAou #bmtsm https://t.co/lq5PJCyr9B